11/13
11:16 am
inzy
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
Medium
Report
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
11/11
08:30 am
inzy
Inozyme Pharma to Present at Upcoming Investor Conferences
Low
Report
Inozyme Pharma to Present at Upcoming Investor Conferences
11/6
08:07 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
11/6
08:07 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
11/5
06:24 pm
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $15.00.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $15.00.
11/5
08:30 am
inzy
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Medium
Report
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
10/25
08:37 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
10/25
08:37 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
10/24
01:15 pm
inzy
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Low
Report
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
10/17
08:30 am
inzy
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
Low
Report
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
10/7
08:30 am
inzy
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
Low
Report
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
9/30
08:40 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Medium
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
9/26
08:00 am
inzy
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
Medium
Report
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
9/12
08:09 am
inzy
Inozyme Pharma, Inc. (NASDAQ: INZY) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $16.00 price target on the stock.
Medium
Report
Inozyme Pharma, Inc. (NASDAQ: INZY) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $16.00 price target on the stock.
8/29
08:30 am
inzy
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
Low
Report
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference